Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 6 Issue 12

Development and Validation of a New Stability Indicating RP-UFLC Method for the Estimation of Imatinib Tablets Using an Ion Pairing Agent

Bandaru Sai Pavan Kumar and Mukthinuthalapati Mathrusri Annapurna*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, Gandhi Institute of Technology and Management, Visakhapatnam, India

*Corresponding Author: Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, Gandhi Institute of Technology and Management, Visakhapatnam, India.

Received: October 19, 2022; Published: November 30, 2022

Abstract

Imatinib is a tyrokinase inhibitor used for the treatment of cancer. A new stability indicating RP-UFLC method has been developed and validated for the determination of Imatinib using an ion pairing agent, tetra butyl ammonium hydrogen sulphate in combination with methanol (45: 55) with flow rate 1.0 mL/min and PDA detection at 281 nm. Imatinib shows linearity over the concentration range 0.05-80 mg/ml and the linear regression equation is found to be y = 62542x + 9790.6 with correlation coefficient 0.9999. The LOD and LOQ were found to be 0.0138 mg/ml and 0.0418 mg/ml respectively. Imatinib was exposed to different stress conditions and results indicate that the method is specific and selective and the method was applied for the pharmaceutical formulations such as Imatinib tablets and was validated as per ICH guidelines.

Keywords: Imatinib; RP-UFLC; Stability Indicating; Validation; ICH Guidelines

References

  1. Druker BJ., et al. “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia”. The New England Journal of Medicine14 (2001): 1031-1037.
  2. Gibbons J., et al. “Phase I and pharmacokinetic study of Imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group”. Journal of Clinical Oncology4 (2008): 570-576.
  3. Druker BJ., et al. “Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome”. The New England Journal of Medicine14 (2001): 1038-1042.
  4. Smita JP., et al. “Development of UV Spectrophotometric method for the determination of Imatinib mesylate (ITM) in bulk and formulation”. Asian Journal of Pharmaceutical and Clinical Research 6 (2013): 54-57.
  5. Nageswari A., et al. “Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms”. Journal of Pharmaceutical and Biomedical Analysis 66 (2012): 109-115. 
  6. María AR., et al. “Validation of an HPLC method for the determination of Imatinib mesylate in pharmaceutical dosage”. Journal of Liquid Chromatography and Related Technologies20 (2005): 3283-3292.
  7. Naga Sindhu S., et al. “Method development and validation of RP-HPLC method for estimation of Imatinib mesylate in pure and pharmaceutical dosage form”. Der Pharmacia Lettre3 (2015): 33-38.
  8. Lalit Mohan N., et al. “Development of a high sensitivity RP-HPLC method and stress testing of Imatinib mesylate”. Journal of Advanced Pharmacy Education and Research3 (2013): 238-243.

       9.    Pratik Shah., et al. “Method development and validation of a stability indicating RP-HPLC method for assay determination of Imatinib in Imatinib mesylate tablets dosage        form”. International Journal of Pharmaceutical Sciences and Research 6.10 (2015): 4453-4468.  

  1. Arun Kumar K., et al. “Analytical method development and validation for the estimation of Imatinib by reverse-phase high-performance liquid chromatography”. Asian Journal of Pharmaceutical and Clinical Research3 (2018): 136-139.
  2. Shah P and Shah R. “A stability-indicating RP-HPLC method development and validation for the related substance determination of imatinib process impurities and their degradation products in tablet dosage form”. International Journal of PharmTech Research 8 (2015): 128-146.
  3. Vadera N., et al. “Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form”. Journal of Pharmaceutical and Biomedical Analysis 43 (2007): 722-726.
  4. Roth O., et al. “Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS”. Clinica Chimica Acta 3-4 (2010): 140-146. 
  5. Schleyer E., et al. “Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations”. Journal of Chromatography B: Analytical Technologies in the Biomed Life Science1 (2004): 23-36.
  6. Velpandian T., et al. “Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples”. Journal of Chromatography B: Analytical Technologies in the Biomed Life Science 804 (2004): 431-434.
  7. Widmer N., et al. “Determination of Imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection”. Journal of Chromatography B: Analytical Technologies in the Biomed Life Science2 (2004): 285-292.
  8. Oostendorp RL., et al. “Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography”. Biomed Chromatography21 (2007): 747-754.
  9. Awidi A., et al. “Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: Methods' comparison”. Leukemia Research in press, (2010).
  10. Masatomo Miura., et al. “Quantitative Determination of Imatinib in Human Plasma with High-Performance Liquid Chromatography and Ultraviolet Detection”. Journal of Chromatographic Science 49 (2011): 412-415.
  11. Le Coutre P., et al. “Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588”. Cancer Chemotherapy and Pharmacology4 (2004): 313-323.
  12. Bende G., et al. “Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study”. Journal of Chromatography Science5 (2010): 334-341. 
  13. Yadav RR., et al. “Determination of potential genotoxic impurities in imatinib mesylate by RP-HPLC method”. Biological Forum-An International Journal 2 (2012): 15-18.
  14. Madireddy V., et al. “Stability-indicative, validated, fast HPLC method for quantification of two genotoxic impurities in imatinib mesylate”. Global Journal of Analytical Chemistry 2 (2011): 198-207.
  15. Ghrib F., et al. “Determination of imatinib and its genotoxic impurities in tablets”. Biological Forum-An International Journal 7 (2015): 1820-1827.
  16. ICH Q2 (R1) Validation of analytical procedures: Text and methodology (2005).
  17. ICH Q1A (R2) Stability testing of new drug substances and products (2003).

Citation

Citation: Bandaru Sai Pavan Kumar and Mukthinuthalapati Mathrusri Annapurna. “Development and Validation of a New Stability Indicating RP-UFLC Method for the Estimation of Imatinib Tablets Using an Ion Pairing Agent". Acta Scientific Pharmaceutical Sciences 6.12 (2022): 77-85.

Copyright

Copyright: © 2022 Bandaru Sai Pavan Kumar and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


Contact US